Ludiomil, maprotiline hydrochloride USP, is a tetracyclic antidepressant, available as 25-mg, 50-mg and 75-mg tablets for oral administration.
Ludiomil is indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Ludiomil is also effective for the relief of anxiety associated with depression.
Published Studies Related to Ludiomil (Maprotiline)
Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. [2007.11]
BACKGROUND: To investigate the effects of antidepressants on glucose-insulin homeostasis, we provided homogenous situation and performed standard procedures to assess the interactions of antidepressants and glucose regulation during hospitalization... CONCLUSIONS: The results suggest that the beta-cell function is hyperbolic in order to offset the insulin resistance following maprotiline treatment. Our findings imply that norepinephrine reuptake inhibitor (NRI) antidepressants might attenuate insulin sensitivity.
Central and peripheral anti-inflammatory effects of maprotiline on carrageenan-induced paw edema in rats. [2010.12]
OBJECTIVE: To explore the site of action of maprotiline, as an atypical antidepressant, on carrageenan-induced paw edema. SUBJECTS: Male Wistar rats were used... CONCLUSION: These results demonstrate that maprotiline has a potent anti-inflammatory effect and this effect is linked to the peripheral and supraspinal actions of the drug.
Effects of repeated maprotiline and fluoxetine treatment on gene expression of catecholamine synthesizing enzymes in adrenal medulla of unstressed and stressed rats. [2010.10]
1 Repeated maprotiline (a noradrenaline reuptake inhibitor) and fluoxetine (a serotonin reuptake inhibitor) treatment on gene expression of catecholamine biosynthetic enzymes were examined in adrenal medulla of unstressed control and chronic unpredictable mild stressed rats... 4 In conclusion, we have demonstrated that repeated administration of fluoxetine enhanced gene transcription of TH and DBH and subsequently stimulates noradrenaline synthesis in adrenal medulla of control and stressed rats.
The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. [2010.03]
The discovery that some selective serotonin transporter- (SSRI) and norepinephrine transporter- (NSRI) targeting antidepressants have the potential to act as anticancer agents adds greatly to their diverse pharmacological application... Although no target has yet been identified for the action of these compounds, the cell death elicited is potent, selective, and worthy of future investigation.
The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. [2009.10]
BACKGROUND: Antidepressant drugs act as potent inhibitors of norepinephrine and/or serotonin reuptake and are widely used with opioids for the treatment of chronic pain. The mechanism of this increased analgesic action is unclear. We compared the antinociceptive effects of the intrathecal administration of morphine with that of a nonselective (amitriptyline) or selective (maprotiline or citalopram) antidepressant drug using the thermal withdrawal test in rats. We also investigated the possible mechanisms involved in the interactions of these drugs... CONCLUSIONS: Selective norepinephrine reuptake inhibitors can significantly increase the intensity and duration of morphine antinociceptive activity via both alpha(2)-adrenergic and opioid receptors. This interaction was not observed with the selective serotonin inhibitor, citalopram.
Clinical Trials Related to Ludiomil (Maprotiline)
Pharmacovigilance in Gerontopsychiatric Patients [Recruiting]
The purpose of this multicenter-study is to investigate safety of psychopharmacological
treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly
people are at higher risk for developing side effects under pharmacological treatment due to
an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore
gerontopsychiatric patients can often not articulate their symptoms clearly, for example due
to pronounced cognitive impairment.
The aim of the study is to gain valid data of possible adverse drug reaction rates, their
potential risk factors and outcome, as well as medical prescription practises.
To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the
five participating study sites.
At Baseline demographic data, previous and present disorders, use of drugs, previous and
present medication, quality of life, cognitive function, physical examination results,
laboratory results and ECG will be assessed.
Afterwards patients are visited weekly and screened for possible adverse drug reactions. All
adverse drug reactions will be coded in the MedDRA-system.
In case of a possible serious adverse drug reaction serum levels of all psychotropic
substances applicated will be assessed. Drug combinations will be analysed using an
established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible
adverse drug reactions are documented continually.
2 weeks after discharge from the ward, patients will be contacted by phone to assess
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
Reports of Suspected Ludiomil (Maprotiline) Side Effects
Wrist Fracture (4),
Saliva Altered (4),
Hallucination, Visual (2),
Confusional State (1),
Fall (1), more >>
Page last updated: 2011-12-09